Alembic announces successful USFDA inspection at joint venture
Aleor Dermaceuticals Ltd., a 60:40 joint venture between Alembic Pharmaceuticals Ltd. and Orbicular Pharmaceutical Technologies Pvt. Ltd., has successfully cleared its first US FDA inspection of its new formulation facility located at Karakhadi, Gujarat, without any observations. The scheduled inspection was carried out between October 15-19, 2018.
Aleor was formed in April 2016 to develop, manufacture and commercialise dermatology products for worldwide markets. Till date the company has filed six ANDAs.
“This is a result of the dedication, commitment and focus of the entire Aleor team to ensure highest quality standards are maintained and we are very excited to build this organisation on a global platform,” said Dr. M.S. Mohan, Founder and Managing Director of Orbicular.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$169/UNIT FOB
2026-10-17
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
UK’s £350 Million Critical Chemicals Fund Enters Formal Review, Offering Up to 50% Support Per Project
-
Colombia Makes Preliminary Ruling in Anti-Dumping Investigation into Chinese DOP Imports
-
EAEU Initiates Review of Anti-Dumping Measures on Chinese Titanium Dioxide, Suspends Duties During Investigation
-
FDA Tracks Industry Dye Removal
-
G20 Pushes Fertilizer Access as Food-Security Risk Rises
-
FDA Lifts Administrative Stay, Restoring Red No. 3 Ban Timeline for Food and Ingested Drugs
-
India Prepares New Seed and Pesticide Laws
-
Syngenta Caught in Trade Crossfire
-
EU Chemicals Regulatory Update: Practical Compliance Actions Following ECHA January 2026 Developments
-
EU PIC Amendment Adds Over 30 Chemicals to Control List and Bans 3 POPs Exports
Recommend Reading
-
![2026 Q1 Chemical Giant Earnings: Supply Contraction, Flat Demand, Full-Scale]()
2026 Q1 Chemical Giant Earnings: Supply Contraction, Flat Demand, Full-Scale "Defense Priority"
-
![U.S. and China Reach Consensus on More Favorable Tariff Treatment for $30 Billion of Goods Each Way]()
U.S. and China Reach Consensus on More Favorable Tariff Treatment for $30 Billion of Goods Each Way
-
![U.S. Section 232 Pharmaceutical Tariffs Take Effect, With 100% Base Rate on Patented Drugs and APIs]()
U.S. Section 232 Pharmaceutical Tariffs Take Effect, With 100% Base Rate on Patented Drugs and APIs
-
![FDA Color Policy Uncertainty Opens a New Chapter for Food Ingredient Reform]()
FDA Color Policy Uncertainty Opens a New Chapter for Food Ingredient Reform
-
![South Korea’s Largest Petrochemical Hub Moves to Cut Cracker Capacity by 40%]()
South Korea’s Largest Petrochemical Hub Moves to Cut Cracker Capacity by 40%
-
![Supply Decreases and Demand Increases, DOP Prices Surge Significantly in January]()
Supply Decreases and Demand Increases, DOP Prices Surge Significantly in January
-
![Premium Global Chemical Sourcing Requests (31 Jan - 4 Feb, 2026)]()
Premium Global Chemical Sourcing Requests (31 Jan - 4 Feb, 2026)
-
![Crude Oil Surge Leads to Significant Increase in This Round of Retail Fuel Prices in China]()
Crude Oil Surge Leads to Significant Increase in This Round of Retail Fuel Prices in China
-
![On March 9, the Isopropyl Alcohol Market in China Experienced a Significant Price Increase]()
On March 9, the Isopropyl Alcohol Market in China Experienced a Significant Price Increase
-
![China's Phenol Market Surges 62% in 9 Days]()
China's Phenol Market Surges 62% in 9 Days
